Syngene to benefit from rupee depreciation, rising demand for research & manufacturing services: CEO Jonathan Hunt

Syngene has raised the revenue guidance for FY23 from mid-teens to high teens due to significant depreciation of rupee against the dollar and signing up new contracts. Rupee depreciated almost 5% since April 1 against the dollar.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DEtS9xn
via IFTTT